Eligibility NCT00408473 Atrial Fibrillation Inclusion Criteria Exclusion Criteria History of more than 1 symptomatic documented AF episode, persistent or permanent AF. Yes
No
History of ablation for previous AF Yes
No
Reversible cause for AF (e.g.thyroid, alcohol, pulmonary embolism, surgery Yes
No
Severe symptoms during AF episode (e.g.syncope, chest pain) Yes
No
All types of treated arrhythmias other than AF Yes
No
History of myocardial infarction (MI), coronary artery disease (CAD), heart failure (I, II, III and IV of New York Heart Association -NYHA- classification) or valvular diseases Yes
No
LVEF - Left ventricular ejection fraction Yes
No
Bradycardia < 40 beats/min and all ECG abnormalities: PR> 240ms or QRS> 120 ms or QTc> 440 ms Yes
No
Brugada Syndrome (disorder) Yes
No
Conduction disturbances: complete bundle branch block (LBBB) or (RBBB), bifascicular block Yes
No
2nd or 3rd degree atrioventricular (AV) block Yes
No
Coronary sinus rhythm disorder Yes
No
Severe hypertension with:Systolic blood pressure >= 180 mmHg, and / or Diastolic blood pressure >= 100 mmHg Yes
No
Left ventricular hypertrophy (LVH) with septal thickness > 14 mm on Echocardiogram Yes
No
(Artificial) Cardiac pacemaker Yes
No
Heart surgery within the last 6 months, or non-stable postoperative condition Yes
No
Renal failure: serum creatinine >= 150 µmol/l or creatinine clearance <= 50 ml/min (Cockroft and Gault formula Yes
No
Uncorrected electrolytic abnormalities Yes
No
Have used recently in the last 3 months prior to the inclusion any of the following treatments: Oral amiodarone, Treatments that lengthen QT interval (e.g.Sultopride, Drugs causing torsades de pointe (e.g.mizolastine, pentamidine, sparfloxacin, moxifloxacin, Bupropion Yes
No
Anti-hypertensive drugs other than permitted in the study: ACE-I, ARB (sartans) and DHP from Calcium channel blockers (CCB Yes
No
